

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: *Drewry et al.*

Confirmation No.: 4610

Application No.: 10/560,502

Group Art Unit: 1624

Filed: December 13, 2005

Examiner: D. Rao

For: INDAZOLO-TETRAHYDROPYRIMIDINE-CARBOXAMIDE DERIVATIVE KINASE  
INHIBITORS (*Title as Amended*)

---

**MAIL STOP AMENDMENT**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**STATEMENT TO SUPPORT FILING AND SUBMISSION  
IN ACCORDANCE WITH 37 CFR §§1.821-1.825**


Sir:

In response to the Notice to Comply with Requirements for Patent Applications containing Sequence Disclosures dated October 2, 2008, the undersigned hereby states that:

1. The submission, filed herewith in accordance with 37 CFR §1.821(g), does not include new matter;
2. The content of the attached paper copy and the attached computer readable copy of the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e), respectively, are the same; and
3. All statements made herein of their own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

Date: 12/24/2008



Kathryn L. Coulter  
Attorney of Record  
Registration No. 45,889

Customer No. 23347  
GlaxoSmithKline  
Corporate Intellectual Property  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709-3398  
Telephone: (919) 483-1467  
Facsimile: (919) 483-7988